BANK VONTOBEL/PUT/BIONTECH ADR/72/0.1/20.09.24 Share Price

Warrant

ON21V

DE000VM65X12

Market Closed - Euronext Paris 16:29:37 19/06/2024 BST
0.151 EUR +11.85% Intraday chart for BANK VONTOBEL/PUT/BIONTECH ADR/72/0.1/20.09.24
Current month+118.84%
1 month+62.37%
Date Price Change
19/06/24 0.151 +11.85%
18/06/24 0.135 +6.30%
17/06/24 0.127 +45.98%
14/06/24 0.087 +29.85%
13/06/24 0.067 +13.56%

Real-time Euronext Paris

Last update June 19, 2024 at 04:29 pm

More quotes

Static data

Product typeWarrants
Buy / SellPUT
Underlying BIONTECH SE
IssuerLogo Issuer Vontobel Vontobel
ON21V
ISINDE000VM65X12
Date issued 27/12/2023
Strike 72 $
Maturity 20/09/2024 (93 Days)
Parity 10 : 1
Emission price 0.26
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.397
Lowest since issue 0.047
Delta-0.15x
Omega 8.165
Premium18.42x
Gearing53.16x
Moneyness 0.8346
Difference Strike -14.27 $
Difference Strike %-19.82%
Spread 0.01
Spread %6.41%
Theoretical value 0.1510
Implied Volatility 42.17 %
Total Loss Probability 79.05 %
Intrinsic value 0.000000
Present value 0.1510
Break even 70.38 €
Theta-0.01x
Vega0.01x
Rho-0x

Company Profile

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Sector
-
More about the company

Ratings for BioNTech SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: BioNTech SE

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
80.33 EUR
Average target price
103.4 EUR
Spread / Average Target
+28.74%
Consensus
  1. Stock Market
  2. Warrants
  3. ON21V Warrant
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW